Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 14/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729455 | 1.00 | UTS2R (0.42) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3729454 | 1.00 | UTS2R (0.42) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3729456 | 1.00 | UTS2R (0.42) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3730202 | 0.94 | UTS2R (0.44) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3730206 | 0.94 | UTS2R (0.44) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3730207 | 0.94 | UTS2R (0.44) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3730205 | 0.94 | UTS2R (0.44) | UTS2RHCRTR1HCRTR2MMP1MMP13 | |
| SCHEMBL3733769 | 0.93 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL3733768 | 0.93 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL3733775 | 0.93 | HCRTR1 (0.46) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | UTS2R 221/4885HCRTR1 1/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.